U.S. DOT FY 2024.1 Phase I Pre-Solicitation Q&A
- To create a new account or to sign in with an existing account please click on “sign in” located at the top right of the page.
- A new pop-up window will open to make a selection, you can use an existing Google or Facebook account to access the site or you might select to create a new account.
- If you choose to access UserVoice with an existing Google or Facebook account, you will be required to enter your login credentials for Google or Facebook and agree to terms of service.
- If you need to create a new account, click "Create an Account" underneath the password box.
- In the next screen, type in the e-mail and click "Verify E-mail".
- Navigate to your inbox and click the link within the e-mail to verify. The link will be generated by noreply@trymagic.com
- That link will be live for 20 minutes. Once that time elapses, you will have to request another one.
- Navigate back to UserVoice, and you will need to provide your name, a password, and agree to terms of service and storage permissions. Click "Create Account".
- Select the research topic your question is related to from the drop-down menu that appears when you begin typing.
- You may add more detail in the Description box(optional). Do NOT attach any files. The U.S. DOT shall not consider any submitted materials other than questions.
- Enter your e-mail address and password.
- When finished, select “Post idea.” If you registered, you will be able to track responses to your post. Please include only one question or comment per post to help us keep the forum organized.
2 results found
-
Proposal submission
Are we required to submit letter of intent or pre-proposal? If so, could you please advise how we can submit this?
1 vote -
Question re delivery of blood products (including blood type, patient permission or refusal?). Possible suggestion to amend/split SBIR topic
Hello --
The topic area "Prehospital Post-Crash Care Systems Improvement" makes certain assumptions that present challenges to implementation "in the real world," today.
Specifically, the solicitation calls for "an innovative treatment for bleeding includes damage control resuscitation (DCR) treatments such as the administration of whole blood, blood products (e.g., red blood cells, fresh frozen plasma, platelets, and cryoprecipitate) and adjuvant therapies (e.g., Recombinant activated factor 7 (rFVIIa))."
But in order for such an approach to be safe and effective, agencies need to know certain biological / physiological as well as clinical details about the people who have been involved in…
1 vote